Abstract
Aim:
To investigate the enhancing effects of chitosan with or without enhancers on nasal recombinant hirudin-2 (rHV2) delivery in vitro and in vivo, and to evaluate the ciliotoxicity of these formulations.
Methods:
The permeation-enhancing effect of various chitosan formulations was estimated by using the permeation coefficient of fluorescein isothiocyanate recombinant hirudin-2 (FITC-rHV2) across the excited rabbit nasal epithelium in vitro. The effect was further evaluated by measuring the blood concentration level after nasal absorption of FITC-rHV2 in rats. The mucosal ciliotoxicity of different formulations was evaluated with an in situ toad palate model.
Results:
Chitosan at a concentration of 0.5% with or without various enhancers significantly increased the permeability coefficient (P) and relative bioavailability (Fr) of FITC-rHV2 compared with the blank control. The addition of 1% sodium dodecylsulfate, 5% Brij35, 5% Tween80, 1.5% menthol, 1% glycyrrhizic acid monoammonium salt (GAM) or 4% Azone into the 0.5% chitosan solution resulted in a further increase in absorption (P<0.05) compared with 0.5% chitosan alone. But co-administration of chitosan with 5% hydroxyl-propyl-beta-cyclodextrin(HP-β-CD), 5%lecithin or 0.1% ethylenediamine tetraacetic acid (EDTA) was not more effective than using the 0.5% chitosan solution alone. Chitosan alone and with 5% HP-β-CD, 0.1% EDTA, 1% GAM or 5% Tween80 was relatively less ciliotoxic.
Conclusion:
Chitosan with or without some enhancers was able to effectively promote the nasal absorption of recombinant hirudin, while not resulting in severe mucosal ciliotoxicity. A chitosan formulation system would be a useful approach for the nasal delivery of recombinant hirudin.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Walenga JM, Pifarre R, Fareed J . Recombinant hirudin as an antithrombotic agent. Drugs Future 1990; 15: 267–80.
Markwardt F, Fink G, Kaiser B, Klocking HP, Nowak G, Richter M, et al. Pharmacological survey of recombinant hirudin. Pharmazie 1988; 43: 202–7.
Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walenga JM, Fareed J . Antithrombotic activity of recombinant hirudin in rat: a comparative study with heparin. Thrombos Res 1989; 54: 435–45.
Markwardt F . The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1–23.
Markwardt F . Prospective clinical use of hirudin as an anticoagulant. Biomed Prog 1990; 3: 19–23.
Han YM, Lu YF, Wang ZH . Studies on the effects of anticoagulant and anti-thrombin after duodenal administration of recombinant hirudin in rats. Chin J Hematol 1999; 20: 483–4.
Yang XY, Wang XT, Zhang XN, Zhang Q . Gastrointestinal absorption of recombinant hirudin-2 in rats. J Pharmacol Exp Ther 2004; 308: 774–9.
Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Varum KM, Artursson P . Chitosan as absorption enhancers for poorly absorbable drugs. 2: Mechanism of absorption enhancement. Pharm Res 1997; 14: 923–9.
Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L . Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997; 86: 509–13.
Jiang XG, Cui JB, Fang XL, Wei Y, Xi NZ . Toxicity of drugs on nasal mucocilia and method of its evaluation. Acta Pharm Sin 1995; 30: 848–53.
Wang HD, Zhou SH . Marking techniques of biomedicine. Beijing: People's Medical Publishing House; 1995.
Griessbach U, Stürzebecher J, Markwardt F . Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347–50.
Hosoya K, Kubo H, Natsume H, Sugibayashi K, Morimoto Y . Evaluation of enhancers to increase nasal absorption using chamber technique. Biol Pharm Bull 1994; 17: 316–22.
Chandler SG, Illum L, Tomas NM . Nasal absorption in rats. II Effect of enhancers on insulin absorption and nasal histology. Int J Pharm 1991; 76: 61–70.
Temesvari LA, Bush JM, Peterson MD, Novak KD, Titus MA, Cardelli JA . Examination of the endosomal and lysosomal pathways in Dictyostelium discoideum myosin I mutants. J Cell Sci 1996; 109: 663–73.
Illum L . Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998; 15: 1326–31.
Illum L, Farraj NF, Davis SD . Chitosan as a novel basal delivery system for peptide drugs. Pharm Res 1994; 11: 1186–9.
Shojaei AH . Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998; 1: 15–30.
Rege BD, Kao JP, Polli JE . Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002; 16: 237–46.
Sugibayashi K, Nakayama S, Seki T, Hosoya K, Morimoto YJ . Mechanism of skin penetration-enhancing effect by laurocapram. Pharm Sci 1992; 81: 58–64.
Wang GS, Zabner J, Deering C, Launspach J, Shao JQ, Bodner M . Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo. Am J Respir Cell Mol Biol 2000; 22: 129–38.
Marttin E, Verhoef JC, Cullander C, Romeijn SG, Nagelkerke JF, Merkus FW . Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancer. Pharm Res 1997; 14: 631–7.
Yang T, Hussain A, Paulson J, Abbruscato TJ, Ahsan F . Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. Pharm Res 2004; 21: 1127–36.
Merkus FW, Verhoef JC, Marttin E, Romeijn, SG, van der Kuy, PH, Hermens WA, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 1999; 36: 41–57.
Yu SY, Zhao Y, Wu FL, Zang X, Lü WL, Zhang H . Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int J Pharm 2004; 281: 11–23.
Maitani Y, Nakamura K, Suenaga H, Kamata K, Takayama K, Nagai T . The effect of soybean-derived sterylglucoside and β-sitosterol β-D-glucoside on nasal absorption in rabbits. Int J Pharm 2000; 200: 17–26.
Kaplun-Frischoff Y, Touitou E . Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids. J Pharm Sci 1997; 86: 1394–9.
Sakai M, Imai T, Ohtake H, Azuma H, Otagiri M . Effects of absorption enhancers on cytoskeletal actin filaments in Caco-2cell monolayers. Life Sci 1998; 63: 45–54.
Sakai M, Imai T, Ohtake H, Azuma H, Otagiri M . Simultaneous use of sodium deoxycholate and dipotassium glycyrrhizinate enhances the cellular transport of poorly absorbed compounds across Caco-2 cell monolayers. J Pharm Biomed Anal 2004; 36: 915–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, Yj., Ma, Ch., Lu, Wl. et al. Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo. Acta Pharmacol Sin 26, 1402–1408 (2005). https://doi.org/10.1111/j.1745-7254.2005.00174.x
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00174.x
